AMENDMENT

Claim 1-21 (Cancelled)

Claim 22. (Previously presented): A composition for inducing specific B cell anergy to a T cell dependent immunogen implicated in an antibody-mediated pathology comprising a plurality of a conjugate, wherein said conjugate comprises:

at least two analog molecules of the immunogen conjugated to a chemically defined valency platform molecule, wherein said analog molecules bind specifically to surface antibody on B cells to which the T cell-dependent immunogen binds specifically, and wherein the analog molecules lack T cell epitopes;

wherein the chemically defined valency platform molecule comprises branching groups, and wherein the valency platform molecule contains a specific number of attachment sites whereby the valency of said platform molecule is defined; and

wherein the molecular weight of the valency platform molecules is substantially homogeneous; and

wherein the valency platform molecules have attachment sites at the same location.

Claim 23. (Previously presented): The composition of claim 22, wherein the branching groups are derived from a functional group selected from the group consisting of diamino acid, triamine, and amino diacid.

Claim 24. (Previously presented): The composition of claim 22, wherein the analog molecules are the same.

Claim 25. (Previously presented): The composition of claim 22 comprising conjugates, wherein a said conjugate comprises four analog molecules.

Claim 26. (Previously presented): The composition of claim 22, wherein the analog molecule is selected from the group consisting of carbohydrates, lipids, lipopolysaccharides, polypeptides, peptides, proteins, glycoproteins, and lipoproteins.

Claim 27. (Previously presented): The composition of claim 22, wherein the valency platform molecules are substantially non-immunogenic.

Claim 28. (Previously presented): The composition of claim 22, wherein the analog molecule is a protein.

Claim 29. (Previously presented): The composition of claim 22, comprising a pharmaceutically acceptable carrier.

Claim 30. (Previously presented): The composition of claim 29, wherein the composition is suitable for injection.

Claim 31. (Previously presented): The composition of claim 22, wherein the conjugate comprises polyethylene glycol.

Claim 32. (Previously presented): The composition of claim 22, wherein the valency platform molecule comprises polyethylene glycol.

Claim 33. (Previously presented): The composition of claim 22, wherein the conjugate comprises polyethylene glycol having the formula $-CH_2(CH_2OCH_2)_rCH_2-$, wherein r=0 to 300.

Claim 34. (Previously presented): The composition of claim 22, wherein the valency platform molecule comprises polyethylene glycol having the formula $-CH_2(CH_2OCH_2)_rCH_2-$, wherein r=0 to 300.

Claim 35. (Previously presented): The composition of claim 22, wherein the valency platform molecule comprises triethylene glycol.

Claim 36. (Previously presented): The composition of claim 22, wherein the antibody mediated pathology is stroke.

Claim 37. (Previously presented): The composition of claim 22, wherein the immunogen is an external immunogen.

Claim 38. (Previously presented): The composition of claim 37, wherein the external immunogen is a biological drug, allergen or a D immunogen associated with Rh hemolytic disease.

Claim 39. (Previously presented): The composition of claim 22, wherein the immunogen is a self-immunogen.

Claim 40. (Previously presented): The composition of claim 39, wherein the immunogen is a cardiolipin.

Claim 41. (Previously presented): The conjugate of claim 39, wherein the self-immunogen is that associated with thyroiditis, diabetes, stroke, male infertility, myasthenia gravis, or rheumatic fever.

Claim 42. (Previously presented): The composition of claim 22, wherein the immunogen and analog molecules are same chemical class.

Claim 43. (Previously presented): The composition of claim 42, wherein the immunogen and the analog molecules are polypeptides.

Claim 44. (Previously presented): The composition of claim 22, wherein the immunogen and the analog molecules are of different chemical classes.

Claim 45. (Previously presented): The conjugate of claim 22, wherein the antibody-mediated pathology is an autoimmune disorder and the associated immunogen is unidentified.

Claim 46. (Previously presented): The conjugate of claim 22, wherein the analog molecules are selected from the group consisting of peptides, polypeptides, and proteins.

Claim 47. (Previously presented): The conjugate of claim 22, wherein the analog molecules are selected from the group consisting of glycoproteins, lipoproteins, carbohydrates, lipids and lipopolysaccharides.

Claim 48. (Previously presented): A method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition of claim 29.

Claim 49. (Previously presented): A method of treating an individual for an antibody-mediated pathology in which undesired antibodies are produced in response to a T cell-dependent immunogen comprising administering a therapeutically effective amount of the composition of claim 29 to the individual.

Claim 50. (Previously presented): A method of making the composition of claim 22, the method comprising forming the conjugates by covalently bonding the analog molecules to the valency platform molecule.

Claim 51. (Previously presented): A method of making the composition of claim 29, the method comprising combining the conjugates with a pharmaceutically acceptable carrier.